NanoViricides Inc. (NNVC)
| Bid | 1.25 |
| Market Cap | 20.8M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -9.36M |
| EPS (ttm) | -0.71 |
| PE Ratio (ttm) | -1.87 |
| Forward PE | -1.19 |
| Analyst | Buy |
| Ask | 1.4 |
| Volume | 106,843 |
| Avg. Volume (20D) | 213,141 |
| Open | 1.35 |
| Previous Close | 1.40 |
| Day's Range | 1.31 - 1.33 |
| 52-Week Range | 0.94 - 3.59 |
| Beta | 0.93 |
About NNVC
NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Human Coronavirus Program for COVID-19 seasonal coronavirus affliction; HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular...
Analyst Forecast
According to 1 analyst ratings, the average rating for NNVC stock is "Buy." The 12-month stock price forecast is $6.5, which is an increase of 388.72% from the latest price.
Stock Forecasts
3 days ago · proactiveinvestors.com
NanoViricides evaluating antiviral drug NV-387 for measles treatmentNanoViricides (NYSE-A:NNVC) has begun evaluating its clinical-stage antiviral NV-387 for the treatment of measles, a disease with no currently approved drug treatment. “A drug for measles is at presen...
2 weeks ago · proactiveinvestors.com
NanoViricides eyes role in US bird flu fight as USDA unveils $100M initiativeThe US Department of Agriculture (USDA) will invest up to $100 million to combat highly pathogenic avian influenza (HPAI), funding research into prevention, therapeutics, and vaccine candidates, the a...
1 month ago · proactiveinvestors.com
NanoViricides says business unaffected by US tariffs, highlights antiviral pipelineNanoViricides (NYSE-A:NNVC) said on Tuesday that its business remains unaffected by US government tariffs, retaliatory trade policies, or federal spending cuts. In a statement, the clinical-stage biot...
1 month ago · proactiveinvestors.com
NanoViricides' NV-387 could provide a crucial missing weapon in the fight against US measles outbreakNanoViricides (NYSE-A:NNVC) believes its broad-spectrum antiviral NV-387 could provide a crucial weapon piece in the fight against the ongoing measles outbreak in the US. The company responded to a re...
1 month ago · proactiveinvestors.com
NanoViricides targets key milestones in 2025 with NV-387 advancing to Phase II trialsNanoViricides (NYSE-A:NNVC) is positioning itself for a pivotal year in 2025, with plans to advance its lead antiviral candidate, NV-387, into multiple Phase II clinical trials. The company is plannin...
